Citations

Clear

904 citation(s) found for "Gordon, S".

Carrier of Porcine von Willebrand's Disease
Owen, Charles A., Bowie, E. J. Walter, Zollman, Paul E., Fass, David N., Gordon, Hymie, Owen, C. A.

Mayo Clinic

American Journal of Veterinary Research | April 3, 2025 | Volume: 35 | Issue: 2 | Pages: 245-248

10.2460/ajvr.1974.35.02.245 Get It

SUMMARY Factor VIII concentrations in plasma, platelet retention, and ear bleeding times were determined on 35 normal pigs, 40 obligate carriers of porcine von Willebrand's disease, and 25 bleeders. The bleeders could be distinguished from the normal pigs by each of the 3 tests. At most, only one-third of the carriers could be distinguished from the normal pigs by any one test. A hemostatic score, derived from the results of the 3 tests, increased the discrimination to slightly more than half. The degrees of abnormality on the 3 diagnostic tests seemed to vary from family to family and might have been related to the sire of the bleeder.
A novel mouse model of diverse tumors derived from epithelial cells
Wang, Lingxiang, Liu, Yang, Jahan‐mihan, Yasmin , He, Gordon, Hu, Jie , Bi, Yan , Ji, Baoan , Jahan-mihan, Yasmin, Wang, Yuxi, Ji, Baoan , Wang, Bin , Liu, Yang, He, Gordon, Wang, Di , Wang, Jiale

Mayo Clinic

Physiological Reports | March 30, 2025 | Volume: 13 | Issue: 7 | Pages: No page available

10.14814/phy2.70289 | PMID 40151103 Get It

AbstractA deeper understanding of pathophysiology, from the initiation of tumors of epithelial cells to the outcomes associated with it, is imperative to test potential interventions for these diseases. However, few models can accomplish this because of the complexity of origin cells and their transformation. We established an epithelial cell original tumor mouse model by conditional KrasG12D activation and tumor suppressor gene p53 deletion specifically in epithelial cells of the whole body using Cytokeratin 19 (CK19) promoter via Cre‐ERT mediation. Multiple tumors derived from epithelial cells developed in this novel model. This model can recapitulate the progress of intestinal, pancreatic, liver, lung, and subcutaneous tumors which derive from epithelial cells. This model is suitable for studying the pathophysiology of tumors derived from epithelial cells and may have the potential to test interventions.
Comparable long-term efficacy of cold and hot EMR of large colon polyps – follow up results of a randomized trial
Pohl, Heiko , Rex, Douglas K. , Barber, Judy, Rastogi, A. , Moyer, Matthew T. , Levenick, John M. , Renteln, Daniel von , Gordon, S., Aslanian, Harry R., Elatrache, Mazen, Elmunzer, J, Keswani, Rajesh N. , Kumta, Nikhil A. , M, Ehl, MacKenzie, Todd A. , Piraka, Cyrus , Barber, J, Gordon, S, Wallace, Michael B. , Pleskow, Douglas K. , M, E Tonzi

Mayo Clinic

Endoscopy | March 27, 2025 | Volume: 57 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1805260 Get It

Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer
Yeku, Oladapo , Tan, Winston , Patnaik, Amita , LoRusso, Patricia , Richardson, Debra L. , Naqash, Abdul Rafeh , Lynam, Sarah , Kyriakopoulos, Christos E. , Dowlati, Afshin , Chamberlain, Marc C. , Yeku, Oladapo O , Tan, Winston W., Richardson, Debra L , Kyriakopoulos, Christos E , Naqash, Abdul Rafeh , Barve, Minal , Wang, Judy , Fu, Siqing , Gordon, Michael S. , Hubbard, Joleen M. , Kummar, Shivaani , Winer, Ira Seth

Mayo Clinic

Journal for ImmunoTherapy of Cancer | March 13, 2025 | Volume: 13 | Issue: 3 | Pages: e010959

10.1136/jitc-2024-010959 | PMID 40081941 Get It

Background Novel treatment options are required in patients with platinum-resistant ovarian cancer (PROC). Myeloid-derived suppressor cells promote a hostile tumor microenvironment and are associated with worse clinical outcomes in PROC. We evaluated the safety and preliminary efficacy of PY159, an agonist antibody to Triggering receptor expressed on myeloid cells-1 (TREM1) that reprograms immunosuppressive intratumoral myeloid cells, and PY314, an antagonist antibody to Triggering receptor expressed on myeloid cells-2 (TREM2) that depletes tumor-associated macrophages, as single agents and in combination with pembrolizumab in subjects with PROC. Methods PY159 and PY314 were individually evaluated in patients with PROC. Patients were treated with monotherapy (PY159 3 mg/kg or PY314 10 mg/kg), based on the recommended dose for expansion derived from the phase 1a studies. At the time of first progression, patients could continue study drug and crossover to combination therapy with pembrolizumab (200 mg) every 3 weeks at the discretion of the investigator. Disease assessment by Response Evaluation Criteria in Solid Tumor version 1.1 was performed every 6 weeks. Results 17 patients were enrolled in the PY159 study (median age 67, range 22–77; median prior therapies 6, range 2–18) and 16 patients in PY314 (median age 65.5, range 49–81; median prior therapies 4, range 2–10). 7 patients in PY159 and 8 patients in PY314 crossed over to combination therapy. Safety events included the following: treatment-related adverse events occurred in 15 patients (88.2%) in PY159 and 9 patients (56.3%) in PY314. Infusion-related reactions occurred in 6 patients (35.3%) in PY159 and 3 patients (18.8%) in PY314. Immune-related adverse events occurred in 13 patients (76.5%) in PY159 (arthralgias) and 1 patient (6.3%) in PY314 (diarrhea). Serious adverse events occurred in 6 patients (36.3%) in PY159 (1 related) and 12 patients (75%) in PY314 (all unrelated). The best radiographic response in PY159 was stable disease in 8/16 patients (50%; median 16 weeks, range 9–33), and in PY314, it was stable disease in 8/16 patients (50%; median 12 weeks, range 6–36). Median PFS was 2.76 months and 2.69 months in PY159 and PY314, respectively. There were no responses in the crossover arm. Conclusions Both PY159 and PY314 were well tolerated, with an acceptable safety profile, as both single agents and in combination with pembrolizumab. Both agents warrant further investigation in heavily pretreated PROC.
Rating certainty when the target threshold is the null and the point estimate is close to the null
Zeng, Linan , Hultcrantz, Monica , Tovey, David , Dahm, Philipp , Brignardello‐Petersen, Romina , Murad, M. Hassan , Izcovich, Ariel , Beer, Hans de , Ragusa, Martín , Zhang, Lingli , Dahm, Philipp , Brignardello-Petersen, Romina , Murad, M Hassan , Izcovich, Ariel , Santesso, Nancy A. , Mustafa, Reem A , Johnston, Bradley C. , Iorio, Alfonso , Guyatt, Gordon

Mayo Clinic

BMJ Evidence-Based Medicine | March 5, 2025 | Volume: 30 | Issue: 3 | Pages: 202-207

10.1136/bmjebm-2024-113077 | PMID 40044276 Get It

When one initially targets the null effect and the point estimate falls close to the null, two challenges exist in rating certainty of evidence. First, when the point estimate is near the null and the data, therefore, suggests little or no effect, rating certainty in a benefit or harm is misleading. Second, since in general the narrower the confidence interval (CI) the more precise the estimate, if the CI is narrow, rating down for imprecision due simply to crossing the null is inappropriate. This paper addresses these issues and provides a solution: to revise the target of certainty rating from a non-zero effect to a little or no effect. This solution requires estimating a range in which the minimal important difference (MID) for benefit and an MID for harm might lie, and thus establishing a range that represents little or no effect. If GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) users are confident that the point estimate represents an effect less than the smallest plausible MID, they will revise their target and rate certainty to a little or no effect. If the entire CI falls within the range of little or no effect, they will not rate down for imprecision. Otherwise (if the CI includes an important effect), they will rate down. Using the solution provided in this paper GRADE users can make an optimal choice of the target of certainty rating.
The landscape of autosomal-dominant Alzheimer’s disease: global distribution and age of onset
Liu, Haiyan , Marsh, Thomas W. , Shi, Xinyu , Bowling, Kevin M. , Ziegemeier, Ellen , Wang, Guoqiao , Cao, Yuchen , Aristel, Alisha, Li, Jessie, Dickson, Alexa , Perrin, Richard J. , Goate, Alison , Fernández, María Victoria , Day, Gregory S. , Doering, Michelle , Daniels, Alisha , Hassenstab, Jason , Supnet, Charlene , Xiong, Chengjie , Berman, Sarah , Ryan, Natalie S. , Huey, Edward D. , Noble, James M. , Roh, Jee Hoon , Laske, Christoph , Sánchez‐Valle, Raquel , Méndez, Patricio Chrem, Chhatwal, Jasmeer P. , Farlow, Martin R. , Xiong, Chengjie , Gordon, Brian A , Ibanez, Laura , Vöglein, Jonathan , Roh, Jee Hoon , Ikeuchi, T , Sánchez-Valle, Raquel , Chhatwal, Jasmeer , Xiong, Chengjie , Rosa-Neto, Pedro , Schofield, Peter R , Bateman, Randall J , Cruchaga, Carlos , Day, Gregory S , Hassenstab, Jason , Fernandez, Maria , Goate, Alison M , Supnet-Bell, Charlene , Berman, Sarah , Noble, James M , Renton, Alan , Gordon, Brian A. , Benzinger, Tammie L.S. , Allegri, Ricardo , Fox, Nick C. , Vöglein, Jonathan , Jucker, Mathias , Ikeuchi, Takeshi , Schofield, Peter R. , Lee, Jae‐Hong , Levey, Allan I. , Lopera, Francisco Javier , Martins, Ralph N. , Niimi, Yoshiki , Bateman, Randall J. , Karch, Celeste M. , McDade, Eric , Llibre‐Guerra, Jorge J.

Mayo Clinic

Brain | February 4, 2025 | Volume: 148 | Issue: 7 | Pages: 2429-2440

10.1093/brain/awaf038 | PMID 39903689 Get It

Abstract We present a comprehensive global analysis of genetic variants associated with autosomal-dominant Alzheimer’s disease (ADAD). A total of 550 variants in the APP, PSEN1 and PSEN2 genes were identified, of which 279 were classified as pathogenic or likely pathogenic based on American College of Medical Genetics and Genomics and the Association for Molecular Pathology criteria, utilizing data from the Dominantly Inherited Alzheimer Network (DIAN), literature and public databases. Symptomatic age at onset (AAO) data were estimated for 227 of these variants, allowing detailed characterization of their frequency, pathogenicity and AAO. Importantly, 226 variants met eligibility criteria for inclusion in disease-modifying clinical trials. Furthermore, we demonstrated the predictive value of mean variant AAO and parental AAO in predicting symptomatic AAO, validated against converters who became symptomatic during follow-up in the DIAN Observational Study. This dataset provides critical insights into the global landscape of ADAD and reveals the genetic and AAO heterogeneity of ADAD variants while refining variant trial eligibility criteria.
MRI and PET findings with long‐term gantenerumab treatment: results from the DIAN‐TU trial
Hornbeck, Russ C. , Li, Yan , Clifford, David B., Santacruz, Anna , Wang, Guoqiao , Klein, Gregory , Baudler, Monika, Doody, Rachelle S., Kerchner, Geoffrey A. , Team, The DIAN‐TU Study, Benzinger, Tammie L.S. , Gordon, Brian A. , McCullough, Austin , Flores, Shaney , Koeppe, Robert A. , Jack, Clifford R. , McDade, Eric , Llibre‐Guerra, Jorge J. , Mills, Susan, Supnet, Charlene , Ibanez, Laura , Atri, Alireza , Bateman, Randall J. , Team, The DIAN‐TU Study

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S8 | Pages: No page available

10.1002/alz.094832 Get It

AbstractBackgroundAnti‐amyloid monoclonal antibody therapies for AD have documented plaque removal on amyloid PET scans. We evaluate the findings for amyloid PET, tau PET, FDG PET and volumetric MRI over the course the open label extension (OLE) for the DIAN‐TU gantenerumab treatment, compared to the last imaging obtained prior to the OLE (to evaluate for potential rebound effects) and in comparison to longitudinal imaging in the DIAN Observational study.MethodThis double‐blind, phase 2/3 trial (2012‐2019), followed by open‐label extension (OLE), investigated varying gantenerumab doses up to 1500 mg SQ q2 weeks [NCT NCT01760005]. We report long‐term amyloid‐plaque removal by PET and findings for metabolic FDG PET and tau PET, and additionally changes of atrophy on volumetric MRI. Imaging measures were secondary outcome analyses. Comparison is made between the treatment cohort and controls (DB placebo participants who didn’t enter OLE, plus external controls from the DIAN OBS). Estimated years to onset was included as a covariate. The gap period of ∼1 year is specifically analyzed to estimate any “rebound” effect on amyloid or tau accumulation or neurodegeneration. Volumetric MRI measures include hippocampal volumes, lateral ventricular volumes, and white matter hyperintensities.ResultIn participants who were asymptomatic at baseline and treated with gantenerumab (n = 53), amyloid‐plaque removal measured by PIB‐PET in Centiloids was dose‐dependent. Few participants had reached completely negative levels (below 24). No statistical significance was found for FDG PET, tau PET, or volumetric MRI, including hippocampal volumes. Impact of the gap period of ∼1 year (gap in treatment) on the rate of amyloid accumulation compared to the rate of accumulation predicted in observational studies of this cohort is under evaluation, as are the other imaging measures.ConclusionWhile no overall effect was observed in the total group for non‐amyloid measures, results suggest dose dependent clearance of amyloid plaque in asymptomatic DIAD mutation carriers following long‐term, high‐dose gantenerumab. The potential “rebound effect” of elevated amyloid accumulation for participants for whom there was a significant gap in therapy between the trial and the OLE is under evaluation and will be presented, as will the variables for FDG PET, tau PET, and volumetric MRI.